BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21411445)

  • 1. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
    Tan DS; Iravani M; McCluggage WG; Lambros MB; Milanezi F; Mackay A; Gourley C; Geyer FC; Vatcheva R; Millar J; Thomas K; Natrajan R; Savage K; Fenwick K; Williams A; Jameson C; El-Bahrawy M; Gore ME; Gabra H; Kaye SB; Ashworth A; Reis-Filho JS
    Clin Cancer Res; 2011 Mar; 17(6):1521-34. PubMed ID: 21411445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
    EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.
    Batista MP; Roffé M; Romero I; López-Guerrero JA; Illueca C; Lopez R; Balieiro Anastácio da Costa AA; De Brot L; Molina JP; Barboza L; Peria FM; Chaud F; Gouvêa Yamada AS; Poveda A; Rego EM
    BMC Cancer; 2023 Jul; 23(1):613. PubMed ID: 37400764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy.
    Xie Y; Kong W; Luo D; Chen S; Zhao X; Zhang HE
    Anticancer Res; 2023 Aug; 43(8):3401-3410. PubMed ID: 37500149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of Chromatin Remodeling Genes and the Rho GTPases
    Arildsen NS; Jönsson JM; Bartuma K; Ebbesson A; Westbom-Fremer S; Måsbäck A; Malander S; Nilbert M; Hedenfalk IA
    Front Oncol; 2017; 7():109. PubMed ID: 28611940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
    Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.
    Yanaihara N; Noguchi Y; Saito M; Takenaka M; Takakura S; Yamada K; Okamoto A
    PLoS One; 2016; 11(9):e0162584. PubMed ID: 27612152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
    Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
    Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
    Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 12. Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
    Katagiri H; Nakayama K; Razia S; Nakamura K; Sato E; Ishibashi T; Ishikawa M; Iida K; Ishikawa N; Otsuki Y; Nakayama S; Kyo S
    Int J Oncol; 2015 Dec; 47(6):2037-44. PubMed ID: 26458502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
    Morikawa A; Hayashi T; Kobayashi M; Kato Y; Shirahige K; Itoh T; Urashima M; Okamoto A; Akiyama T
    Oncol Rep; 2018 Jul; 40(1):309-318. PubMed ID: 29749539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
    Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
    Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
    Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
    Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.
    Bennett JA; Safdar N; Segal JP; Lastra RR; Oliva E
    Int J Gynecol Pathol; 2021 Mar; 40(2):156-164. PubMed ID: 32897960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.
    Goh XY; Rees JR; Paterson AL; Chin SF; Marioni JC; Save V; O'Donovan M; Eijk PP; Alderson D; Ylstra B; Caldas C; Fitzgerald RC
    Gut; 2011 Oct; 60(10):1317-26. PubMed ID: 21478220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.